Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Digestive System Diseases

Rare Diseases

Carcinoma

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Fallopian Tube Neoplasms

Peritoneal Neoplasms

Abdominal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Peritoneal Diseases

Genital Neoplasms, Female

Urogenital Neoplasms

Fallopian Tube Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Endocrine Gland Neoplasms

Ovarian Diseases

Endocrine System Diseases

Gonadal Disorders

Ovarian Cancer

Ovarian Epithelial Cancer

Fallopian Tube Cancer

For all the patients include in the studie :

* Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)
* Tissue samples (tumor tissue and healthy tissue) collected during the surgery

In parallel to this biological collection, standardized clinical data will be entered into a database

* Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)
* Tissue samples (tumor tissue and healthy tissue) collected during the surgery

Biological collection

BLEUSE Jean-Pierre, M.D

BLEUSE Jean-Pierre, MD

COLOMBO Pierre-Emmanuel, M.D

A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical datas to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to epithetial ovarian cancer, Fallopian tube cancer and Primitive peritoneal cancer.

A Clinical and Biological Database is a collection of reliable, prospective and representative datas.

This collection, provided to the scientific community, will help to develope research programs such as :

* Cinicals and biological predictive factors of treatments response
* Identification of biological tumoral markers associate with survival
* Identification of prognosic factors after recidivism
* Diagnostics tests optimisation and follow-up from blood samples ( Circulating Tumor Cells (CTC) )
* Developing strong preclinical models. Those models would be later used to test alternative treatments and would help to identify new biomarkers

Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers

Development of a Prospective and Monocentric Cinical and Biological Database in Epithelial Ovarian Cancer, Fallopian Tube Cancer and Primitive Peritoneal Cancer

The proportion of patients who consent to participate in the study among the screened patients

Institut du Cancer de Montpellier - Val d'Aurelle

Biobanking educational DVD and booklet kit developed by the Tampa Bay Community Network (TBCCN) Center. English kit is entitled "Biobanking Hope for a Cancer Cure", and Spanish kit is entitled "Biobanco: Una esperanza de cura para el cancer."

Biobanking educational Brochure developed by the National Cancer Institute. English brochure is entitled "Providing your Tissue for Research: What you need to Know", Spanish brochure is entitled "Lo que usted debe saber antes de dar sus tejidos para investigación médica."

Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.

TBCCN-developed educational materials

Participants will be asked to view the English biobanking educational Brochure entitled "Providing your Tissue for Research: What you need to Know", or Spanish brochure entitled "Lo que usted debe saber antes de dar sus tejidos para investigación médica."

NCI-developed educational materials

Clement Gwede, PhD, MPH, RN

The purpose of this study is to evaluate English and Spanish language educational materials that inform the community about a type of cancer research that involves the collection, storage, and processing of biospecimens. Part A of this study involved creating surveys about biospecimen donation and research. Now, a randomized controlled trial (RCT) will begin to evaluate education materials about biospecimen donation and research.

Phase II consists of two independent randomized controlled trials. Each trial is being conducted independently to test English and Spanish language materials (75 subjects each).

The project addresses gaps in information by developing and validating English and Spanish language instruments to measure knowledge of and attitudes towards biospecimen donation and banking, as well as intention to donate biospecimens to a biobank (Part A). Once developed, the instruments will be used to evaluate biobanking educational priming tools by conducting two independent RCTs. Wherein English educational materials will be tested with 75 participants recruited from an urban clinic, and Spanish educational materials will be tested with 75 participant recruited form a rural community health center network. For each RCT following baseline assessment, participants will be randomized to either: 1) educational priming tools (DVD and booklet) developed by the Tampa Bay Community Cancer Network (TBCCN); or 2) an NCI-developed brochure entitled "Providing Your Tissue for Research: What You Need to Know." Seven to 28 days later participants will be given a telephone follow up interview.

Evaluating Biobanking Educational Tools

Administered at baseline and between 7 and 28 days after enrollment. Description: A validated 16-item questionnaire measuring knowledge about biobanking.

Administered at baseline and between 7 and 28 days after enrollment. Description: A validated 15-item questionnaire measuring attitudes toward biobanking.

Administered at baseline and between 7 and 28 days after enrollment. Description: A validated 12-item questionnaire measuring self-efficacy in regards to donating a biospecimen to a biobank.

Administered at baseline. Description: A single item measuring intentions to donate a biospecimen to a biobank.

Administered at follow-up (between 7 and 28 days after enrollment). Description: A validated 11-item questionnaire measuring participant's confidence in making a decision about donating a biospecimen (O'Connor M.A. Decision Self-efficacy Scale. 1995; www.ohri.ca/decisionaid).

Administered at baseline and between 7 and 28 days after enrollment. Description: A validated 10-item questionnaire measuring trust related to organizations, facilities, and people that may be involved in research.

H. Lee Moffitt Cancer Center and Research Institute

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Intestinal Diseases

Rectal Diseases

For all the patients include in the study :

* Paraffin tissue samples (if applicable) collected during pre-therapeutic rectal biopsy
* Blood samples collected at different times : Before any treatment and Before surgery if the patient received pre-operative radiochemotherapy

In parallel to this biological collection, standardized clinical data will be entered into a database

Blood samples are collected at different times :

* Before any treatment
* After pre-operative radiochemotherapy and before surgery (if applicable)

BLEUSE Jean-pierre

ROUANET Philippe, MD-PhD

A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to Rectum Cancer.

In France, colorectal cancer is the second major cause of cancer-related death with 17 000 cases per year. Rectal carcinoma represents 40% of colorectal cancers.

Locally advanced rectal carcinoma raises the issue of both the oncological control, local and general, and the therapeutic morbidity. Currently, pre-operative radiochemotherapy associated with radical proctectomy (TME) is the standard treatment. Radiochemotherapy improves the local control but with enhanced postoperative morbidity and poor functional results.

Moreover, some patients have no downstaging (around 1/3) and the metastatic risk remains about 30%.

Then, compliance to adjuvant chemotherapy is generally poor after radical proctectomy.

Tumor response to preoperative treatment is the major prognostic factor which reveals tumor aggressiveness. Nevertheless, at present, there are no predictive markers of tumor response.

Progresses in rectal cancer management are related to sharing biological and clinical resources with scientific community.

A clinical and biological collection will allow to :

* develop research programs on predictive markers to pre-operative radiochemotherapy or prognostics factors to disease recurrence
* optimize diagnostic and follow-up tests
* develop new biomarkers to improve patient's therapeutic management

In this context, the Montpellier Cancer Institute (ICM) decided to initiate a biological collection biomedical research dedicated to the tissular and blood samples of patients with colorectal cancer.

Development of a Clinical and Biological Database in Rectum Cancer

Development of a Monocentric and Prospective Clinical and Biological Database in Rectum Cancer

Sarcoma

Neoplasms, Connective and Soft Tissue

Soft Tissue Sarcoma

For all the patients include in the study :

* Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue)
* MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery
* circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery
* radiotherapy toxicity : Blood samples collected before the radiotherapy

In parallel to this biological collection, standardized clinical data will be entered into a database

Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue

Paraffin tissue samples

MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery radiotherapy toxicity : Blood samples collected before the radiotherapy

blood sample

FIRMIN Nelly, MD

A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to Sarcoma

Liposarcomas (LPS) are soft tissue tumours of mesenchymal origin. The most common histological subtypes, represented by well differenciated Lipsarcomas (WD-LPS) and dedifferenciated (DD-LPS), are characterized by the quasi-systematic amplification of the q13-15 of chromosome 12 containing the Mdm2 gene.

The systematic amplification of the Mdm2 gene is such that it is used clinically to distinguish WD/DD-LPS from other types of sarcomas. These observations raise key questions about the high selection pressure that leads to the almost systematic amplification of Mdm2 during the development of these LPS.

Mdm2 is an oncoprotein whose roles in p53 tumour suppressor degradation are broadly described. However, the different inhibitors targeting this interaction were disappointing in clinical trials.

Recently a team from the U1194 INSERM unit of the IRCM which collaborates in this project showed by a pan-genomics analysis, that Mdm2 is recruited to chromatin within a multiproteic complex having as target a transcriptional program involved in the metabolism and in particular in the biosynthesis of the serin.

This clinical-biological basis will allow the continuation of this research project on liposarcomas and the development of new research projects on other histological types of sarcomas.

Establishment of a Prospective Clinical-biological Database

Development of a Monocentric and Prospective Clinical and Biological Database in Sarcoma

number of collection of tissue samples (tumour tissue and healthy tissue) in patients operated on a sarcoma associated with clinical data.

Number of collection of blood in patients operated on a sarcoma associated with clinical data.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers	NCT03976999	Carcinoma, Ovar... Fallopian Tube ... Peritoneal Neop...	Biological coll...	18 Years -	Institut du Cancer de Montpellier - Val d'Aurelle
Evaluating Biobanking Educational Tools	NCT01672944	Neoplasm	TBCCN-developed... NCI-developed e...	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers	NCT03976999	Carcinoma, Ovar... Fallopian Tube ... Peritoneal Neop...	Biological coll...	18 Years -	Institut du Cancer de Montpellier - Val d'Aurelle
Development of a Clinical and Biological Database in Rectum Cancer	NCT04006951	Rectal Neoplasm...	Biological coll...	18 Years -	Institut du Cancer de Montpellier - Val d'Aurelle
Establishment of a Prospective Clinical-biological Database	NCT04458792	Sarcoma	Paraffin tissue... blood sample	18 Years -	Institut du Cancer de Montpellier - Val d'Aurelle
Establishment of a Prospective Clinical-biological Database	NCT04458792	Sarcoma	Paraffin tissue... blood sample	18 Years -	Institut du Cancer de Montpellier - Val d'Aurelle
Development of a Clinical and Biological Database in Rectum Cancer	NCT04006951	Rectal Neoplasm...	Biological coll...	18 Years -	Institut du Cancer de Montpellier - Val d'Aurelle
Evaluating Biobanking Educational Tools	NCT01672944	Neoplasm	TBCCN-developed... NCI-developed e...	18 Years -	H. Lee Moffitt Cancer Center and Research Institute

Spots Global Cancer Trial Database for biological specimen banks